Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 10/20 | 0.57 |
| ▸ | NMUR1 | Q9HB89 | 10/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | NPY4R | P50391 | 3/20 | 0.49 |
| ▸ | NPY1R | P25929 | 2/20 | 0.49 |
| ▸ | NPY2R | P49146 | 2/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.49 |
| ▸ | GNRHR | P30968 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5167427 | 0.88 | KISS1R (0.67) | KISS1RPTGS1GNRHR | |
| SCHEMBL5167437 | 0.88 | KISS1R (0.67) | KISS1RPTGS1GNRHR | |
| SCHEMBL31351849 | 0.87 | NMUR2 (0.59) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| Hydrochloric Acid SCHEMBL11644061 | 0.86 | OPRK1 (0.56) | NMUR2NMUR1KISS1ROPRM1OPRK1 | |
| SCHEMBL11884805 | 0.85 | NMUR2 (0.61) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL11884818 | 0.85 | NMUR2 (0.61) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL5499951 | 0.85 | NPY4R (0.58) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL30567819 | 0.84 | KISS1R (0.64) | KISS1RPTGS1GNRHR | |
| SCHEMBL11100120 | 0.84 | KISS1R (0.66) | KISS1RPTGS1GNRHR | |
| Hydrochloric Acid SCHEMBL11665303 | 0.84 | NMUR2 (0.58) | NMUR2NMUR1KISS1RNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230087806-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087806-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | NMUR2 1686/4885NMUR1 2355/4885KISS1R 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.